Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Eutilex Inc.

    Client Virtual Booth

    EUTILEX INC

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Eutilex Inc
    korearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    1401, 17th Street, Dae-lung Techno-Town, Kasan-dong 1, 25, Geumcheon-gu, Seoul
    Telephone
    Telephone
    02-3402-7310
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.eutilex.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    GenScript ProBio Congratulates Eutilex’s IND Clearance from MFDS

    Details:

    EU307 is a fourth-generation CAR-T therapy which targets GPC3-positive solid cancer. It is expected to improve the viability of CAR-T cells and their ability to attack cancer cells through the secretion of cytokine (IL-18).


    Lead Product(s): EU307

    Therapeutic Area: Oncology Product Name: EU307

    Highest Development Status: Phase IProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: GenScript ProBio

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 07, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Details:

    Studied by NOV and Eutilex with humanized mice, EU101(NOV1801), effectively eradicated human tumors and showed synergistic anti-tumor activity with immune checkpoint blockade.


    Lead Product(s): EU101

    Therapeutic Area: Oncology Product Name: EU101

    Highest Development Status: IND EnablingProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Samsung Biologics

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 27, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search